Impact of concurrent medication use on statin adherence and refill persistence

Archives of Internal Medicine

Volumn 164, Issue 21, 2004, Pages 2343-2348

  Grant, Richard W ^a,b,c   O'Leary, Kathleen M ^a   Weilburg, Jeffrey B ^a,b   Singer, Daniel E ^a,b   Meigs, James B ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANGINA PECTORIS AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANXIOLYTIC AGENT; ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; MEVINOLIN; NITRATE; PRAVASTATIN; SIMVASTATIN;

ADULT; ANXIETY; ARTICLE; COHORT ANALYSIS; COMORBIDITY; DEMOGRAPHY; DEPRESSION; DIABETES MELLITUS; FEMALE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL;

ADULT; AGE FACTORS; COHORT STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; POLYPHARMACY; PRESCRIPTIONS, DRUG; SOCIOECONOMIC FACTORS; TIME FACTORS;

EID: 8844252920     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.164.21.2343     Document Type: Article

References (34)

1. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995;25:305-313.
2. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: the Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998;21:518-524.
3. Redfield MM, Jacobsen SJ, Burnett JCJ, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289:194-202.
4. American Diabetes Association clinical practice recommendations 2001. Diabetes Care. 2001;24(suppl 1):S1-S133.
5. Hunt SA, Baker DW, Chin MW, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure); International Society for Heart and Lung Transplantation; Heart Failure Society of America. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the .1995 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the International Society for Heart and Lung Transplantation; endorsed by the Heart Failure Society of America. Circulation. 2001;104:2996-3007.
6. Sacks FM, Pfeffer MA, Moye LA, et al; Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335: 1001-1009.
7. Gotto AM Jr. Lipid management in patients at moderate risk for coronary heart disease: insights from the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Med. 1999;107:36S-39S.
8. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
9. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
10. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA. 1998;279:1458-1462.
11. Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs: do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med. 1995;332:1125-1131.
12. Fincke BG, Miller DR, Spiro AR. The interaction of patient perception of over-medication with drug compliance and side effects. J Gen Intern Med. 1998; 13:182-185.
13. Asai Y, Heller R, Kajii E. Hypertension control and medication increase in primary care. J Hum Hypertens. 2002;16:313-318.
14. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997; 50:105-116.
15. Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with type 2 diabetes: a retrospective cohort study. Diabet Med. 2002;19:279-284.
16. Schectman JM, Bovbjerg VE, Voss JD. Predictors of medication-refill adherence in an indigent rural population. Med Care. 2002;40:1294-1300.
17. Grant RW, Devita NG, Singer DE, Meigs JB. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care. 2003;26:1408-1412.
18. Billups SJ, Malone DC, Carter BL. The relationship between drug therapy non-compliance and patient characteristics, health-related quality of life, and health care costs. Pharmacotherapy. 2000;20:941-949.
19. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288: 455-461.
20. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288:462-467.
21. Steiner JF, Koepsell TD, Finn SD, Inui TS. A general method of compliance assessment using centralized pharmacy records: description and validation. Med Care. 1988;26:814-823.
22. Kaplan E, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc. 1958;53:457-481.
23. Cox DR. Regression models and life tables. J R Stat Soc Ser B Stat Methodol. 1972;34:187-202.
24. Christensen DB, Williams B, Goldberg HI, Martin DP, Engelberg R, LoGerfo JP. Assessing compliance to antihypertensive medications using computer-based pharmacy records. Med Care. 1997;35:1164-1170.
25. Nuesch R, Schroeder K, Dieterle T, Martina B, Battegay E. Relation between insufficient response to antihypertensive treatment and poor compliance with treatment. BMJ. 2001;323:142-146.
26. Rosenstock IM, Strecher VJ, Becker MH. Social learning theory and the Health Belief Model. Health Educ Q. 1988;15:175-183.
27. Grant RW, Pirraglia PA, Meigs JB, Singer DE. Trends in complexity of care from 1991 to 2000 for patients with diabetes. Arch Intern Med. 2004;164:1134-1139.
28. Shulman NB, Martinez B, Brogan D, Carr AA, Miles CG. Financial cost as an obstacle to hypertension therapy. Am J Public Health. 1986;76:1105-1108.
29. Soumerai SB, Avorn J, Ross-Degnan D, Gortmaker S. Payment restrictions for prescription drugs under Medicaid: effects on therapy, cost, and equity. N Engl J Med. 1987;317:550-556.
30. Moorman PG, Hames CG, Tyroler HA. Socioeconomic status and morbidity and mortality in hypertensive blacks. Cardiovasc Clin. 1991;21:179-194.
31. Martin BC, McMillan JA. The impact of implementing a more restrictive prescription limit on Medicaid recipients. Med Care. 1996;34:686-701.
32. Schafheutle EI, Hassell K, Noyce PR, Weiss MC. Access to medicines: cost as an influence on the views and behaviour of patients. Health Soc Care Community. 2002;10:187-195.
33. Tseng C-W, Brook RH, Keeler E, Mangione CM. Impact of an annual dollar limit or "Cap" on prescription drug benefits of Medicare patients. JAMA. 2003;290: 222-227.
34. Soumerai SB, Ross-Degnan D. Inadequate prescription-drug coverage for Medicare enrollees: a call to action. N Engl J Med. 1999;340:722-728.